Related Experiment Video

Updated: May 24, 2026

Co-transplantation of Human Ovarian Tissue with Engineered Endothelial Cells: A Cell-based Strategy Combining Accelerated Perfusion with Direct Paracrine Delivery
07:40

Co-transplantation of Human Ovarian Tissue with Engineered Endothelial Cells: A Cell-based Strategy Combining Accelerated Perfusion with Direct Paracrine Delivery

Published on: May 16, 2018

Accumulation of nanocarriers in the ovary: a neglected toxicity risk?

Andreas Schädlich1, Stefan Hoffmann, Thomas Mueller

  • 1Department of Pharmaceutical Technology and Biopharmaceutics, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.

Journal of Controlled Release : Official Journal of the Controlled Release Society
|February 25, 2012
PubMed

Insights

Nanocarrier drug delivery systems accumulate in rodent ovaries, posing a potential toxicity risk. Early in vivo studies are crucial for pharmaceutical research and may reveal new ovarian therapy avenues.

Area of Science:

  • Pharmacology
  • Toxicology
  • Biomedical Engineering

Background:

  • Nanocarrier systems are integral to modern pharmaceutical therapies.
  • Potential toxicity risks associated with nanocarrier drug delivery systems require thorough investigation.
  • Understanding nanocarrier biodistribution is essential for drug development.

Purpose of the Study:

  • To investigate the in vivo biodistribution and potential accumulation of various nanocarrier systems in rodent ovaries.
  • To assess the toxicity implications of nanocarrier accumulation in ovarian tissues.
  • To explore the potential for targeted ovarian therapies using nanocarriers.

Main Methods:

  • Intravenous administration of structurally diverse nanocarriers (nanoparticles, nanocapsules, nanoemulsions) and soluble polymers in different mouse species and Wistar rats.
  • In vivo and ex vivo multispectral fluorescence imaging for characterizing nanocarrier enrichment.
  • Confocal laser scanning microscopy for detailed visualization of nanocarrier localization within ovarian tissues.

Main Results:

  • Significant accumulation of various nanocarriers, but not soluble polymers, was detected in rodent ovaries following intravenous administration.
  • High local enrichment of nanoparticles, nanocapsules, and nanoemulsions was consistently observed in specific ovarian locations across all tested animals.
  • Multispectral fluorescence imaging and confocal microscopy confirmed the presence and localization of nanocarriers within ovarian structures.

Conclusions:

  • Nanocarrier accumulation in ovaries represents a potential toxicity concern that warrants further investigation in human health.
  • The findings underscore the importance of early and comprehensive in vivo studies in pharmaceutical research to identify potential off-target effects.
  • The observed ovarian accumulation of nanocarriers may pave the way for developing novel targeted ovarian drug delivery strategies.

More Related Videos

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Accurate Follicle Enumeration in Adult Mouse Ovaries07:27

Accurate Follicle Enumeration in Adult Mouse Ovaries

Published on: October 16, 2020

Related Concept Videos

Oogenesis02:07

Oogenesis

In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
Drug Distribution: Tissue Binding01:21

Drug Distribution: Tissue Binding

Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...